ClinicalTrials.gg
CompletedNCT06479382Updated Aug 22, 2025

Study of the ETX-4143 2.0 Device in Subjects With Eye Pain

An interventional study of ETX-4143 2.0 in Eye Pain, sponsored by EyeCool Therapeutics, Inc.. Completed at 4 sites in Australia. Open to participants aged 22 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by EyeCool Therapeutics, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
22 Years to 90 Years
Sex
All
01

Study summary

A prospective early-feasibility study to evaluate the safety and effectiveness of the ETX-4143 2.0 device. The device is intended to treat subjects with eye pain

Read the detailed description

A prospective early-feasibility study to evaluate the safety and effectiveness of the ETX-4143 2.0 device. The device is intended to treat subjects who suffer from eye pain an do not get relieve from current medications or clinical treatments. Thirty eyes will be enrolled and randomized 2:1 to the investigational treatment or a sham treatment. Improvement in self-reported ocular pain and clinical safety measures will be evaluated.

It is anticipated that the learnings from the study will be used to design future study of the ETX-4143 2.0 device.

All subjects will be followed for 8 weeks. Subjects will only have the worse eye treated if both eyes meet the inclusion/exclusion criteria.

A medical monitor will evaluate the safety of the study on a continual basis.

02

Conditions studied

  • Eye Pain

Browse trials for

03

In context

Eye Pain

31 studies on the registry are indexed under Eye Pain; 7 are open to participants now.

This study's enrollment of 31 is below the median of 55 across 28 interventional studies indexed under Eye Pain.

Browse Eye Pain studies →

Lead sponsor

EyeCool Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of eye pain with no relief from currently available medications or treatments
  • Willing to forgo participation in any other clinical stud for the duration of this study
  • Demonstrate sufficient cognitive awareness to comply with the examination process
  • Willing and able to comply with the schedule for follow-up visits
  • Willing to participate in the study as evidenced by signing an document

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study time period, including the follow-up period
  • Any active ocular infection or active ocular inflammation at the time of the screening visit
  • History of herpes keratitis, non-healing corneal epithelial defects, or neurotrophic keratopathy due to corneal herpetic disease, stem cell deficiency, diabetic keratopathy, severe lagophthalmos, or topical anesthetic abuse
  • Any history of significant eye surgery with the prior 90 days
  • Planned eye surgery during the entire study
  • Participation in any clinical study of an product within 30 days prior to enrollment
  • Any history of serious, poorly controlled systemic or ophthalmic condition that could compromise the subject's ability to comply with the protocol or compromise their safety
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Investigational

    Treatment with the ETX-4143 2.0 device

    Device: ETX-4143 2.0

  • Sham comparator
    Control

    Treatment with a sham ETX-4143 2.0 device

    Device: ETX-4143 2.0

Interventions

  • DeviceETX-4143 2.0

    Treatment of the eye with the ETX-4143 2.0 device

06

What researchers measure

Primary outcomes

  1. Reduction of eye pain

    Patient reported level of eye pain

    Time frame: Eight weeks

  2. Adverse events

    Adverse events related to treatment

    Time frame: Eight weeks

07

Study locations

4 sites
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Ophthamic Trials Australia
    Brisbane, Queensland 4005, Australia
  • Innovative Eye Care
    Adelaide, South Australia 5000, Australia
  • Sunshine Eye Surgeons
    St Albans, Victoria 3021, Australia
08

References and documents

Publications

  • Galor A, Rapuano C, Epitropoulos A, Weiss J, Pflugfelder S, Gupta P, Dhaliwal D, Periman L, Henderson BA, Nguyen TT, Samarawickrama C, Wu H, Stryjewski T, Stefater JA, Hinds M, Bhindi P, Ifantides C. A Randomized Double-Masked Study Evaluating Safety and Efficacy of a Novel Topical Cooling Device for Chronic Ocular Surface Pain. Ophthalmol Ther. 2026 Jun;15(6):2033-2050. doi: 10.1007/s40123-026-01392-3. Epub 2026 May 8. PubMed 42101550 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Nov 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Jun 28, 2024
StartActual
Aug 1, 2024
Primary completionActual
Nov 29, 2024
CompletionActual
Nov 29, 2024
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06479382
Lead sponsor
EyeCool Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 28, 2024
Start date
Aug 1, 2024
Primary completion
Nov 29, 2024
Completion
Nov 29, 2024
Last update
Aug 22, 2025

Study contacts

Patrick R Casey, OD
study chair · VP of Clinical Develpment

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion